Calidi Biotherapeutics targets Q1 2027 clinic entry for CLD-401 cancer program
CLDI•Preclinical update for CLD-401 at AACR conference
Calidi Biotherapeutics presented new preclinical data on its CLD-401 cancer program at the AACR Drug Discovery and Development Conference on July 23, 2026.
The update indicated tumor-cell killing activity in human and mouse models, supporting the program’s development rationale without disclosing detailed performance measures.
Calidi reiterated expectations to enter CLD-401 into the clinic in Q1 2027, setting a near-term milestone for the RedTail platform.
New findings also covered an in situ T-cell engager approach, including a candidate targeting EpCam, extending the platform’s product scope.
